검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Administration of ceralasertib and olaparib (Administration of ceralasertib and olaparib) AstraZeneca·Adv Solid Malig - H&N SCC, ATM Pro… ORR 19% |
|---|---|
Overview Program | Administration of ceralasertib and olaparib |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Adv Solid Malig - H&N SCC, ATM Pro / Def |
Overview Indication | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.. Mutations in genes encoding proteins involved the DNA damage response (DDR) occur in up to 20% of patients with cancer. It is unknown whether poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, alone or in combination with ATR or AKT inhibitors, have histology-agnost… |
Clinical Primary efficacy | ORR 19% |
Clinical ORR | 19% |
Clinical PFS | 7.3 |
Clinical OS | 20.4 |
Clinical Result source | ClinicalTrials.gov NCT03330847 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Administration of ceralasertib and olaparib (Administration of ceralasertib and olaparib) AstraZeneca·Adv Solid Malig - H&N SCC, ATM Pro… ORR 19% |
|---|---|
Overview Program | Administration of ceralasertib and olaparib |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Adv Solid Malig - H&N SCC, ATM Pro / Def |
Overview Indication | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.. Mutations in genes encoding proteins involved the DNA damage response (DDR) occur in up to 20% of patients with cancer. It is unknown whether poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, alone or in combination with ATR or AKT inhibitors, have histology-agnost… |
Clinical Primary efficacy | ORR 19% |
Clinical ORR | 19% |
Clinical PFS | 7.3 |
Clinical OS | 20.4 |
Clinical Result source | ClinicalTrials.gov NCT03330847 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교